ANL vs RCUS vs AGEN vs TGTX vs IMVT

For growth investors, TG Therapeutics, Inc.

(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus -100. 0% for Adlai Nortye Ltd. (ANL). TG Therapeutics, Inc. (TGTX) offers the better valuation at 17. 9x trailing P/E (35. 9x forward), making it the more compelling value choice. Analysts rate Adlai Nortye Ltd. (ANL) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Agenus Inc.

is actually cheaper at 4. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -96. 8% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: TGTX returned +605. 4% versus AGEN's -95. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TG Therapeutics, Inc.

(TGTX) is the lower-risk stock at 0. 65β versus Agenus Inc. 's 2. 26β — meaning AGEN is approximately 247% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 107% for Adlai Nortye Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TG Therapeutics, Inc.

(TGTX) is pulling ahead at 87. 3% versus -100. 0% for Adlai Nortye Ltd. (ANL). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -833. 1% for Adlai Nortye Ltd. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus -996. 4% for ANL. At the gross margin level — before operating expenses — ANL leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 4. 2x forward P/E versus 35. 9x for TG Therapeutics, Inc. — 31. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANL: 151. 9% to $26. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, TG Therapeutics, Inc.

(TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), +605. 4% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TGTX: +605. 4%, AGEN: -95. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ANL is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; TGTX is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.